N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype

[1]  A. Rosato,et al.  A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. , 2013, European journal of cancer.

[2]  William C. Eckelman,et al.  First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[3]  H. Klocker,et al.  Anterior gradient 2 and 3 – two prototype androgen‐responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells , 2013, The FEBS journal.

[4]  D. Ruderman,et al.  Anterior gradient 2 (AGR2): Blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype , 2013, The Prostate.

[5]  Shankar Vallabhajosula,et al.  Prostate-specific membrane antigen-based imaging. , 2013, Urologic oncology.

[6]  K. Pummer,et al.  Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness , 2013, The Prostate.

[7]  S. Horvath,et al.  Prostate cancer cell phenotypes based on AGR2 and CD10 expression , 2012, Modern Pathology.

[8]  Jeonghoon Lee,et al.  Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate. , 2012, Bioorganic & medicinal chemistry letters.

[9]  W. Ellis,et al.  Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine , 2012, The Prostate.

[10]  B. Ring,et al.  A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. , 2012, American journal of clinical pathology.

[11]  Jian Wang,et al.  Spondin-2 (SPON2), a More Prostate-Cancer-Specific Diagnostic Biomarker , 2012, PloS one.

[12]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[13]  K. Korkmaz,et al.  Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells , 2012, Molecular and Cellular Endocrinology.

[14]  Chris Metcalfe,et al.  Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study , 2012, BMJ : British Medical Journal.

[15]  I. Mills,et al.  The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis , 2011, The EMBO journal.

[16]  Daniel R. Dries,et al.  γ-Secretase-regulated Proteolysis of the Notch Receptor by Mitochondrial Intermediate Peptidase* , 2011, The Journal of Biological Chemistry.

[17]  K. Korkmaz,et al.  Ubiquitously expressed hematological and neurological expressed 1 downregulates Akt-mediated GSK3β signaling, and its knockdown results in deregulated G2/M transition in prostate cells. , 2011, DNA and cell biology.

[18]  B. Vojtesek,et al.  Anterior gradient 2: a novel player in tumor cell biology. , 2011, Cancer letters.

[19]  J. Edwards,et al.  GRP78 up‐regulation is associated with androgen receptor status, Hsp70–Hsp90 client proteins and castrate‐resistant prostate cancer , 2011, The Journal of pathology.

[20]  R. Eeles,et al.  The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine , 2010, PloS one.

[21]  K. Ryan,et al.  Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells , 2010, Cell Death and Disease.

[22]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[23]  Hsiang-Cheng Chi,et al.  Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasion. , 2010, Endocrine-related cancer.

[24]  J. Schalken,et al.  The use of PCA3 in the diagnosis of prostate cancer , 2009, Nature Reviews Urology.

[25]  I. Mills,et al.  LYRIC/AEG-1 Is Targeted to Different Subcellular Compartments by Ubiquitinylation and Intrinsic Nuclear Localization Signals , 2009, Clinical Cancer Research.

[26]  H. Lilja,et al.  Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer , 2009, Current opinion in urology.

[27]  Anbupalam Thalamuthu,et al.  A Genome-Wide Association Study Identifies Novel and Functionally Related Susceptibility Loci for Kawasaki Disease , 2009, PLoS genetics.

[28]  Mark J. Dunning,et al.  BASH: a tool for managing BeadArray spatial artefacts , 2008, Bioinform..

[29]  Xiang Li,et al.  Overexpression of JKTBP1 induces androgen‐independent LNCaP cell proliferation through activation of epidermal growth factor‐receptor (EGF‐R) , 2008, Cell biochemistry and function.

[30]  Zheng Wang,et al.  The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. , 2008, Cancer research.

[31]  B. Zheng,et al.  High expression of PSM‐E correlated with tumor grade in prostate cancer: A new alternatively spliced variant of prostate‐specific membrane antigen , 2007, The Prostate.

[32]  S. Groshen,et al.  Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. , 2007, Human pathology.

[33]  S. Tavaré,et al.  beadarray: R classes and methods for Illumina bead-based data , 2007, Bioinform..

[34]  D. Neal,et al.  Labeling and identification of LNCaP cell surface proteins: A pilot study , 2007, The Prostate.

[35]  S. Gamble,et al.  Mechanisms of androgen receptor repression in prostate cancer. , 2006, Biochemical Society transactions.

[36]  J. Konvalinka,et al.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer , 2006, The EMBO journal.

[37]  M. Conkright,et al.  CREB: the unindicted cancer co-conspirator. , 2005, Trends in cell biology.

[38]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[39]  P. Sharp,et al.  Cre-lox-regulated conditional RNA interference from transgenes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Konvalinka,et al.  Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. , 2004, European journal of biochemistry.

[41]  J. Konvalinka,et al.  Identification of the N‐glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity , 2004, Protein science : a publication of the Protein Society.

[42]  I. Krantz,et al.  A giant novel gene undergoing extensive alternative splicing is severed by a Cornelia de Lange-associated translocation breakpoint at 3q26.3 , 2004, Human Genetics.

[43]  Camilo Rojas,et al.  Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. , 2002, Analytical biochemistry.

[44]  S. Weed,et al.  Focal Adhesion Kinase: a regulator of focal adhesion dynamics and cell movement , 2000, Oncogene.

[45]  A. Woodard,et al.  Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. , 1999, Cancer research.

[46]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[47]  T. Matsui,et al.  Cloning and characterization of a cDNA encoding a novel heterogeneous nuclear ribonucleoprotein-like protein and its expression in myeloid leukemia cells. , 1998, Journal of biochemistry.

[48]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[49]  J. Guan,et al.  Phosphorylation of Tyrosine 397 in Focal Adhesion Kinase Is Required for Binding Phosphatidylinositol 3-Kinase* , 1996, The Journal of Biological Chemistry.

[50]  Norbert Gretz,et al.  Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. , 2005, Anticancer research.

[51]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[52]  A. Renshaw,et al.  Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  P. Walsh,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. , 1997, The Journal of urology.